Retail pharmacy chain Walgreen Co. and Theranos Inc., a developer of devices and mobile apps designed to test blood at low cost, have settled their $140 million breach of contract lawsuit.

Theranos, which raised $686.3 million in funding according to Crunchbase.com but has been mired for more than a year in defending itself against allegations that it misrepresented results and violated federal regulations, announced the settlement yesterday in a terse press release.

“Theranos has entered a confidential settlement agreement with Walgreen Co. and Walgreens Boots Alliance, Inc. resolving all claims among those parties,” Theranos says. “The agreement will result in the dismissal of Walgreens’ lawsuit against Theranos, with no finding or implication of liability.”

Founded in 2003 by Elizabeth Holmes, once touted as the world’s youngest self-made female billionaire, Theranos developed blood testing equipment such as a finger stick that draws a very small sample of blood from the capillaries in a patient’s hand, and mobile health apps to access blood test results and find nearby labs and wellness clinics. The company said its “lab-on-a-chip” technology, which required drawing a much smaller amount of blood from patients and screened blood for a wider array of metrics than conventional blood testing and would make blood testing cheaper, more convenient and accessible to consumers.

Walgreens and Theranos announced an arrangement in 2013 whereby Palo Alto, Calif.-based Theranos would deploy its blood testing equipment and technicians at 40 Theranos Wellness Centers located at Walgreens’ stores in Arizona.

But beginning in 2015, Theranos faced growing concerns from multiple healthcare organizations about the effectiveness of its blood test technologies. In July 2016, Theranos received sanctions from the Centers for Medicare & Medicaid Services. The federal agency revoked the company’s laboratory testing certification and prohibited Theranos from owning or operating a lab for two years.

 Theranos next announced that it would close its laboratory operations and wellness centers to work on miniature medical testing machines. In June 2016 Walgreens told Theranos it was terminating its relationship and closing operations at all 40 Theranos Wellness Centers at its Arizona stores. Walgreens also filed a $140 million lawsuit for breach of contract.

“In light of the voiding of a number of test results, and as the Centers for Medicare and Medicaid Services has rejected Theranos’ plan of correction and considers sanctions, we have carefully considered our relationship with Theranos and believe it is in our customers’ best interests to terminate our partnership,” Walgreens senior vice president and chief health care commercial market development officer Brad Fluegel noted at the time.

Walgreens, which has yet to issue a statement on the settlement with Theranos, filed suit in the United States District Court in Delaware for repayment of $100 million and a $40 million convertible note.

In announcing the Walgreens settlement, Theranos also notes the future focus of the company is changing. “Over the past 16 months, the company has built a new senior management team, changed the composition and structure of its board of directors, installed an expert technology and scientific advisory board, and implemented a new quality and compliance program,” Theranos says.